{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:35:39Z","timestamp":1790400939798,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T00:00:00Z","timestamp":1466380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ADMA Biologics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10875-016-0308-z","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T02:31:10Z","timestamp":1466389870000},"page":"590-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy, Safety, and Pharmacokinetics of a New 10\u00a0% Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Richard L.","family":"Wasserman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Lan","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,20]]},"reference":[{"key":"308_CR1","first-page":"133","volume":"10","author":"ML Boyle","year":"2008","unstructured":"Boyle ML, Scalchunes C. Impact of intravenous immunoglobulin (IVIG) treatment among patients with primary immunodeficiency diseases. Pharm Policy Law. 2008;10:133\u201346.","journal-title":"Pharm Policy Law"},{"issue":"6","key":"308_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1067\/mai.2002.124999","volume":"109","author":"PJ Busse","year":"2002","unstructured":"Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001\u20134.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"308_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jaci.2012.03.025","volume":"129","author":"C Cunningham-Rundles","year":"2012","unstructured":"Cunningham-Rundles C, Maglione PJ. Common variable immunodeficiency. J Allergy Clin Immunol. 2012;129(5):1425\u20136. e3.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"308_CR4","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and immunology. J Allergy Clin Immunol. 2006;117(4):S525\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"308_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2217\/imt.14.67","volume":"6","author":"S Albin","year":"2014","unstructured":"Albin S, Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy. 2014;6(10):1113\u201326.","journal-title":"Immunotherapy"},{"key":"308_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","volume":"31","author":"I Quinti","year":"2011","unstructured":"Quinti I. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315\u201322.","journal-title":"J Clin Immunol"},{"key":"308_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21\u201330.","journal-title":"Clin Immunol"},{"issue":"6","key":"308_CR8","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","volume":"125","author":"M Lucas","year":"2010","unstructured":"Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"308_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0091-6749(99)70067-9","volume":"104","author":"M Berger","year":"1999","unstructured":"Berger M. Goals of therapy in antibody deficiency syndromes. J Allergy Clin Immunol. 1999;104:911\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"308_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","volume":"122","author":"VR Bonagura","year":"2008","unstructured":"Bonagura VR, Marchlewski R, Cox A, et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210\u20132.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"308_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","volume":"39","author":"DE Furst","year":"2009","unstructured":"Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009;39(1):18\u201329.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"308_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0022-3476(99)70246-5","volume":"134","author":"P Quartier","year":"1999","unstructured":"Quartier P, Debr\u00e9 M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589\u201396.","journal-title":"J Pediatr"},{"issue":"4","key":"308_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.vaccine.2004.06.023","volume":"23","author":"P Sastre","year":"2004","unstructured":"Sastre P, Melero JA, Garcia-Barreno B, et al. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. Vaccine. 2004;23(4):435\u201343.","journal-title":"Vaccine"},{"issue":"2","key":"308_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12325-010-0101-y","volume":"28","author":"JR Groothuis","year":"2011","unstructured":"Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness II: immunoprophylaxis. Adv Ther. 2011;28(2):110\u201325.","journal-title":"Adv Ther"},{"key":"308_CR15","doi-asserted-by":"crossref","unstructured":"The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93\u20139.","DOI":"10.1542\/peds.99.1.93"},{"issue":"21","key":"308_CR16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJM199311183292102","volume":"329","author":"J Groothuis","year":"1993","unstructured":"Groothuis J. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. NEJM. 1993;329(21):1524\u201330.","journal-title":"NEJM"},{"issue":"5","key":"308_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","volume":"102","author":"American Academy of Pediatrics: Committee on Infectious Diseases and Committee on Fetus and Newborn","year":"1998","unstructured":"American Academy of Pediatrics: Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211\u201316.","journal-title":"Pediatrics"},{"key":"308_CR18","unstructured":"FDA Guidance. Guidance for industry safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. June 2008."},{"issue":"Suppl 1","key":"308_CR19","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.earlhumdev.2011.01.012","volume":"87","author":"B Paes","year":"2011","unstructured":"Paes B, Manzoni P. Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Hum Dev. 2011;87 Suppl 1:S55\u20138.","journal-title":"Early Hum Dev"},{"issue":"Suppl 1","key":"308_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1526-0542(09)70010-7","volume":"10","author":"B Faroux","year":"2009","unstructured":"Faroux B. Insights from the Sixth Global Experts\u2019 Meeting (GEM) on respiratory viruses: special populations. Paediatr Respir Rev. 2009;10 Suppl 1:21\u20132.","journal-title":"Paediatr Respir Rev"},{"issue":"2","key":"308_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0022-3476(96)70245-7","volume":"129","author":"EA Simoes","year":"1996","unstructured":"Simoes EA, Groothius JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129(2):214\u20139.","journal-title":"J Pediatr"},{"issue":"1","key":"308_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/bmt.2015.212","volume":"51","author":"MS Boukhvalova","year":"2016","unstructured":"Boukhvalova MS. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 2016;51(1):119\u201326.","journal-title":"Bone Marrow Transplant"},{"key":"308_CR23","unstructured":"Falsey AR. Polyclonal human intravenous immune globulin (IGIV) with high-levels of RSV neutralizing antibodies: a summary of animal and human studies. Annual Conference of the Canadian Blood and Marrow Transplant Group June 11\u201314, 2014."},{"key":"308_CR24","unstructured":"Mond J. Treatment of normal and immune suppressed cotton rats with IVIG containing high neutralizing titer anti-RSV antibody. 9th International Respiratory Syncytial Virus Symposium November 2014."},{"issue":"3","key":"308_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1586\/1744666X.2014.891438","volume":"10","author":"RL Wasserman","year":"2014","unstructured":"Wasserman RL. A new intravenous immunoglobulin: bivigam for primary humoral immunodeficiency. Expert Rev Clin Immunol. 2014;10(3):325\u201337.","journal-title":"Expert Rev Clin Immunol"},{"key":"308_CR26","unstructured":"BIVIGAM Prescribing Information. 2013."},{"key":"308_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00431","volume":"6","author":"JS Orange","year":"2015","unstructured":"Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6:1\u20137.","journal-title":"Front Immunol"},{"key":"308_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10875-009-9348-y","volume":"30","author":"M Berger","year":"2010","unstructured":"Berger M, Pinciaro PJ, Althaus A, et al. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321\u20139.","journal-title":"J Clin Immunol"},{"key":"308_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","volume":"141","author":"S Jolles","year":"2011","unstructured":"Jolles S, Bernatowska E, de Garcia J, et al. Efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141:90\u2013102.","journal-title":"Clin Immunol"},{"key":"308_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","volume":"29","author":"MR Stein","year":"2009","unstructured":"Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137\u201344.","journal-title":"J Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-016-0308-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0308-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:14:14Z","timestamp":1581956054000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-016-0308-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,20]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s10875-016-0308-z","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,20]]},"assertion":[{"value":"18 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}